| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 2 nov 2026Próximo | Q3 2026 | Antes de apertura | 3,81 | 1,21 B |
31 ago 2026
WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).
26 ago 2026
IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.
25 ago 2026
In a new SEC filing on August 24, it was revealed that Emerson, EVP at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities
21 ago 2026
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
20 ago 2026
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
19 ago 2026
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
18 ago 2026
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day August 13, 2026 8:00 AM EDTCompany ParticipantsMichael Erickson - CEO, President & DirectorJulie...
14 ago 2026
IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre
2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.
13 ago 2026
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...
11 ago 2026
Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.
WESTBROOK, Maine, August 11, 2026--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.
8 ago 2026
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
6 ago 2026
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
5 ago 2026
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.
Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.
4 ago 2026
Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call
IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.
IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...
The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero Consortium for Buyers (NZCB) by Cisco, Juniper Networks (now part of Hewlett Packard Enterprise), Bio-Rad Laboratories, Cadence Design Systems, IDEXX Laboratories, Inc., PTC, and a large healthcare company, which signed an aggregated virtual power purchase agreement (VPPA) with Southern Power Com
IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.
